Myasthenia Gravis

AstraZeneca has announced FDA approval of Ultomiris, a long-acting C5 complement inhibitor for the treatment of adults with generalized myasthenia gravis.

Clinical-stage biopharmaceutical company Immunovant Inc. announced it has reached agreement with the FDA to initiate a phase 3 study of batoclimab in patients with myasthenia gravis in the first half of the year.

Healio Neurology’s five most-viewed stories in December highlight a study on increased sun exposure lowering children’s MS risk, FDA approval of a treatment for myasthenia gravis and research on a self-administered examination that may quickly identify mild cognitive impairment conversion to dementia.

Merck announced it has entered an agreement to acquire Chord Therapeutics, a biotech company that focuses on rare neuroinflammatory diseases, to expand its neurology pipeline.

The FDA announced the approval of Vyvgart for treatment of the chronic autoimmune, neuromuscular disease myasthenia gravis in adults who are positive for acetylcholine receptor antibody.

Although rituximab was safe and well tolerated in acetylcholine receptor antibody-positive generalized myasthenia gravis, researchers noted low probability of it significantly reducing steroid use at 1 year.

Nearly half of individuals in a study about activities of daily living among more than 1,000 patients with myasthenia gravis reported disease symptoms associated with an “unsatisfactory” state, according to findings published in Neurology.

Patients with myasthenia gravis — particularly those post-thymectomy — demonstrate an increased odds for having systemic lupus erythematosus, according to a speaker at the 2021 North American Young Rheumatology Investigator Forum.

Efgartigimod, a human IgG1 antibody designed to decrease pathogenic IgG autoantibody levels, demonstrated efficacy and tolerability among patients with generalized myasthenia gravis, according to findings published in The Lancet Neurology.

Researchers observed a significant difference in the rate of complete stable remission among several surgical methods for thymectomy in myasthenia gravis, according to results of a meta-analysis published in Neurology.